Side-by-side comparison of AI visibility scores, market position, and capabilities
Holland MI sodium-ion battery manufacturer (founded 2012) — PERMANENTLY CLOSED September 2025; $373M raised, $65.7M 2024 revenue, first US commercial sodium-ion (50,000-cycle Prussian blue), gigafactory funding failure forced shutdown.
Natron Energy was a Holland, Michigan-based sodium-ion battery manufacturer — the first US company to achieve commercial-scale production of sodium-ion batteries — that permanently ceased operations in September 2025 due to unresolved funding issues, with Sherwood Partners (an insolvency advisory firm) engaged to sell the company's assets. Founded in 2012 by Colin Wessells during his PhD research at Stanford University, Natron developed a breakthrough Prussian blue electrode chemistry for sodium-ion batteries that achieved 50,000+ cycle life (5x greater than lithium-ion, 50x greater than lead acid), 5-15 minute full recharge capability, nonflammable chemistry (safe even when physically penetrated), and power density of 40W/Wh (4x lithium-ion). The company raised $373 million total from investors including Khosla Ventures, Intel Capital, and the California Energy Commission. Natron's flagship BlueRack battery cabinets (250kW and 500kW configurations) targeted data center UPS/backup power, EV fast charging, and industrial peak shaving applications — markets where the 50,000+ cycle life justified the higher upfront cost versus lithium-ion alternatives. The Holland, Michigan manufacturing facility achieved commercial production in 2024, generating $65.7 million in revenue. In December 2024, Wendell Brooks (former President of Intel Capital) became CEO with Wessells transitioning to Chief Technology and Product Officer, and the company announced a $1.4 billion gigafactory plan for Rocky Mount, North Carolina (24 GWh/year capacity, 40x the Michigan plant) — but unresolved funding for the gigafactory expansion and operational costs forced the company to cease all operations in September 2025.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.